We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$46.6M
Cap. Flow
+$25.8M
Cap. Flow %
13.71%
Top 10 Hldgs %
88.03%
Holding
89
New
10
Increased
1
Reduced
31
Closed
14

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$38.5M
2
LQDA icon
Liquidia Corp
LQDA
+$268K
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$213K
4
AVBP icon
ArriVent BioPharma
AVBP
+$208K
5
KRYS icon
Krystal Biotech
KRYS
+$207K

Top Sells

Rank Stock Value
1
SERA icon
Sera Prognostics
SERA
+$4.87M
2
DFTX
Definium Therapeutics
DFTX
+$613K
3
TYRA icon
Tyra Biosciences
TYRA
+$613K
4
CYTK icon
Cytokinetics
CYTK
+$547K
5
CMPS
Compass Pathways
CMPS
+$538K

Sector Composition

Rank Sector Weight
1 Healthcare 14.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
76
Agios Pharmaceuticals
AGIO
$2.05B
– –
-15,000
Closed -$507K
APGE icon
77
Apogee Therapeutics
APGE
$10.2B
– –
-2,500
Closed -$210K
CELC icon
78
Celcuity
CELC
$4.7B
– –
-2,000
Closed -$228K
CMPX icon
79
Compass Therapeutics
CMPX
$436M
– –
-30,000
Closed -$159K
CYTK icon
80
Cytokinetics
CYTK
$11B
– –
-8,300
Closed -$547K
ERAS icon
81
Erasca
ERAS
$6.66B
– –
-17,327
Closed -$280K
INBX icon
82
Inhibrx
INBX
$1.89B
– –
-6,927
Closed -$466K
KALV
83
DELISTED
KalVista Pharmaceuticals
KALV
– –
-10,795
Closed -$217K
LEGN icon
84
Legend Biotech
LEGN
$4.04B
– –
-12,000
Closed -$217K
PRAX icon
85
Praxis Precision Medicines
PRAX
$10.6B
– –
-1,500
Closed -$483K
SERA icon
86
Sera Prognostics
SERA
$85.6M
– –
-2,396,685
Closed -$4.87M
SMMT icon
87
Summit Therapeutics
SMMT
$11.5B
– –
-10,223
Closed -$194K
TYRA icon
88
Tyra Biosciences
TYRA
$1.57B
– –
-16,000
Closed -$613K
UTHR icon
89
United Therapeutics
UTHR
$22.3B
– –
-350
Closed -$208K
1 2 3
4

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q2 2026 Portfolio in Review

As of Q2 2026, PSP Research held 89 positions worth $188M, up 33% from $141M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

PSP Research deployed $25.8M of net new capital in Q2 2026, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Liquidia Corp: 5,000 shares worth $399K.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 24% a quarter earlier.

On the sell side, the largest reduction was Definium Therapeutics, an estimated $613K trimmed.

  • PSP Research's largest Q2 2026 buy was Liquidia Corp: 5,000 shares worth $399K.
  • PSP Research added most to State Street SPDR S&P Biotech ETF in Q2 2026, an estimated $38.5M increase.
  • PSP Research's biggest Q2 2026 reduction was Definium Therapeutics, cutting an estimated $613K.
  • PSP Research fully exited Sera Prognostics in Q2 2026, selling an estimated $4.87M.
  • PSP Research's ten largest holdings make up 88% of its $188M portfolio in Q2 2026.
  • PSP Research opened 10 new positions and closed 14 in Q2 2026.
  • PSP Research's portfolio value rose 33% quarter-over-quarter to $188M.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.